Dr. Ho Ning Wong completed a Higher Diploma in Chemical Technology in the Department of Applied Biology and Chemical Technology at The Hong Kong Polytechnic University in 1999. She then enrolled at the Hong Kong University of Science and Technology (HKUST), and completed her Bachelor of Science Degree with First Class Honors in Chemistry in 2001. Thereafter, she conducted research for her PhD degree at HKUST on the topic "Studies on Artemisone and Other Artemisinin Antimalarials" in conjunction with Bayer AG, Leverkusen, Germany. Under the same industrial collaborative activities, she carried out postdoctoral research on the artemisinin antimalarials, and became engaged in consulting and R and D activities. Such activities were carried out first at HKUST, and then from 2014, in the Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa. She took up an appointment as Research Fellow in the Rural Health Research Institute at Charles Sturt University, Orange, NSW, Australia, in July 2023, where she is engaged in overseeing the setting up of a synthetic medicinal chemistry laboratory for the preparation of drug candidates under Good Laboratory Practice (GLP) conditions, associate supervision of postgraduate students, and responsibility for instrumentation.

            In relation to research activities, at HKUST, Dr. Wong was involved in the preparation of 'cold' analogues of radio-labelled antimalarial drugs including the HKUST-developed artemisone conducted under a research and development contract with Bayer Zentralforschung AG, Leverkusen, Germany and Bayer Health Care, Wuppertal, Germany. She participated in the technology transfer from HKUST to Bayer AG for preparation of 14-C radio­labelled artemisone, including a site visit and advising Bayer personnel on synthetic chemistry, and preparation of artemisone metabolites. She also prepared new amino-artemisinin and 11-aza-artemisinin derivatives for malaria and cytotoxicity studies. She was involved in the stability assessment of the artemisinin derivative artesunate and analysis of decomposition products in rectal capsules under a joint project with Dr. Melba Gomes, Tropical Diseases Research (TDR) of the World Health Organization (WHO), Geneva. She also prepared polar chloroquine and primaquine analogues for selective targeting of liver stages of the malaria parasite, and was involved in the process optimization for scale-up for industrial preparation of artemisone for Bayer Zentralforschung and then Bayer Health Care AG. At HKUST, she also examined the mechanism of action of artemisinin antimalarials in which it was illustrated that artemisinins behave as oxidant drugs.

At the Centre of Excellence for Pharmaceutical Science (Pharmacen), North-West University (NWU), Potchefstroom, South Africa, she participated in the supervision of the South African Medical Research Council Flagship Project "MALTB REDOX: Development to the Clinical Phase of Oxidant and Redox Drug Combinations for Treatment of Malaria, TB and Related Diseases" and the SA NRF Project "Rational Development of Combinations of Known and Novel Drugs for Chemotherapy of Cancer." She was involved in mentoring of students and personnel in use of inert atmosphere techniques, anhydrous solvents and techniques for trans­ferring air-sensitive reagents, and she synthesized active artemisinin-based compounds which possess nanomolar activities against cancer cell lines. She was a member of the Pharmaceutics Research Committee for evaluation of postgraduate research proposals at NWU.

Dr. Wong has co-authored 28 publications in the primary scientific literature, 11 scientific reports for Bayer AG and the World Health Organization, Geneva, and has been involved in the preparation and presentation of 19 conference papers.